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Abstract 
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition characterised 
by fatigue and post-exertional malaise. Its pathogenesis is poorly understood. GDF15 is a circulating protein secreted 
by cells in response to a variety of stressors. The receptor for GDF15 is expressed in the brain, where its activation 
results in a range of responses. Among the conditions in which circulating GDF15 levels are highly elevated are mito-
chondrial disorders, where early skeletal muscle fatigue is a key symptom. We hypothesised that GDF15 may repre-
sent a marker of cellular stress in ME/CFS.
Methods: GDF15 was measured in serum from patients with ME/CFS (n = 150; 100 with mild/moderate and 50 with 
severe symptoms), “healthy volunteers” (n = 150) and a cohort of patients with multiple sclerosis (n = 50).
Results: Circulating GDF15 remained stable in a subset of ME/CFS patients when sampled on two occa-
sions ~ 7 months (IQR 6.7–8.8) apart, 720 pg/ml (95% CI 625–816) vs 670 pg/ml (95% CI 598–796), P = 0.5. GDF15 
levels were 491 pg/ml in controls (95% CI 429–553), 546 pg/ml (95% CI 478–614) in MS patients, 560 pg/ml (95% CI 
502–617) in mild/moderate ME/CFS patients and 602 pg/ml (95% CI 531–674) in severely affected ME/CFS patients. 
Accounting for potential confounders, severely affected ME/CFS patients had GDF15 concentrations that were sig-
nificantly increased compared to healthy controls (P = 0.01). GDF15 levels were positively correlated (P = 0.026) with 
fatigue scores in ME/CFS.
Conclusions: Severe ME/CFS is associated with increased levels of GDF15, a circulating biomarker of cellular stress 
that appears which stable over several months.
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Background
Myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) is a debilitating condition with an estimated 
population prevalence of between 0.2 and 2.6% and the 
most common prevalence estimates in between 0.2 
and 0.7% [1–3]. ME/CFS is defined by the presence of 
unexplained persistent or recurrent fatigue for a period 
greater than 6  months that results in a reduction in an 
individual’s ability to maintain previously tolerated levels 
of occupational, social, educational and personal activ-
ity. The activity-limiting symptomatology is heterogene-
ous and not limited to fatigue [4–6]. The aetiology of ME/
CFS remains elusive and although a range of mechanisms 
have been proposed the main focus of investigation has 
centred on immune system dysregulation although no 
consensus exists [7–9]. There is growing interest into the 
potential contribution of abnormalities in muscle bio-
energetics to the phenotype of muscle fatigue [10, 11]. 
Oxidative stress, mitochondrial dysfunction, acidosis and 
impaired AMP kinase activity have all been proposed as 
possible mechanisms contributing to muscle fatigue in 
ME/CFS [10, 12]. Abnormal fatigue and post-exertional 
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malaise are debilitating symptoms of ME/CFS, which 
could potentially be explained by abnormalities in energy 
metabolism. The diagnosis of ME/CFS is based on clini-
cal parameters and as yet there is no biochemical marker 
for the condition, where attempts to identify disease spe-
cific biomarkers have been hampered by the incomplete 
understanding of the disease pathophysiology. Growth 
differentiation factor 15 (GDF15) is a circulating peptide 
which has recently been shown to have a weight lower-
ing effect when administered to rodents and non-human 
primates [13–15]. A number of observations have led us 
to speculate as to the role of GDF15 in ME/CFS, con-
sidering it as a potential disease biomarker and perhaps 
a contributor to the symptomatology observed. Firstly, 
there is emerging evidence that GDF15 has evolved as a 
signal of cellular stress [16] with growing interest in its 
role as a biomarker for disorders of mitochondrial func-
tion [17]. Secondly, it has also been shown that GDF15 
increases following physical activity, which is interest-
ing when considered in the context of post-exertional 
symptoms described in ME/CFS [18]. Thirdly, in rodent 
models, increases in circulating GDF15 are reported to 
be associated with reduced physical activity [19, 20]. To 
date GDF15 has not been formally studied in the context 
of ME/CFS. To address this, we measured circulating 
levels of GDF15 in a clinically and biochemically pheno-
typed ME/CFS cohort, and compared them with distinct 
cohorts of healthy individuals and patients with multi-
ple sclerosis (MS), all consenting participants from the 
UK ME/CFS Biobank (UKMEB) [21].
Methods
Participant recruitment
Potential participants of the UK ME/CFS Biobank 
(UKMEB) were invited from the collaborating National 
Health System (NHS) primary and secondary care and 
those who have severe symptoms (being bed- or home-
bound) were mainly invited by support groups. The 
participants received an invitation pack (containing invi-
tation letter from their doctor, information sheet, con-
sent forms, and a questionnaire for initial assessment 
of symptoms). Once the signed consent form and the 
symptom assessment questionnaire were received by the 
research team, a clinical member of the team contacted 
potential participants for booking appointments, or to 
explain a possible exclusion at that stage. Participation in 
the study required participants to attend one of the col-
laborating clinics, or when not possible, due to severity of 
disease, they were visited at home by the study research 
nurse. Participants consented to be reassessed in 6 to 
12  months, when all the procedures for clinical assess-
ment, including questionnaires, standardised assess-
ment instruments, blood collections were repeated, as a 
longitudinal follow-up [22]. The inclusion criteria are: (i) 
being of 18 years to 60 years old and (ii) having a clini-
cal diagnosis of ME/CFS, according to CDC-1994 [4] or 
Canadian consensus [5] criteria, confirmed by a clini-
cal researcher after clinical assessment and laboratory 
tests, the later for differential diagnoses; or (iii) having 
a confirmed diagnosis of MS given by a consultant neu-
rologist [23] or (iv) being healthy. We excluded from the 
recruitment those who had: (i) used drugs known to alter 
immune function (e.g. azathioprine, cyclosporine, meth-
otrexate, steroids), and/or anti-viral medications and 
vaccinations in the preceding 3 months; (ii) a history of 
acute and chronic infectious diseases such as hepatitis B 
and C, tuberculosis, HIV (but not herpes virus or other 
herpes virus infection); and/or (iii) other severe illness 
and severe mood disorders. Pregnant women and those 
within 12 months post-partum and/or currently lactating 
were also excluded; as well as the healthy individuals who 
had any history of fatiguing illnesses and/or other condi-
tions that would exclude a diagnosis of ME/CFS (in those 
with fatigue).
Clinical assessments
Questionnaires
During the appointments for clinical assessment and 
blood sample collection, an additional extended ques-
tionnaire was handed to potential participants contain-
ing questions related to: (i) personal and family history, 
(ii) socio-demographics, (iii) potential risk factors—e.g. 
smoking and activity levels, among others, and (iv) symp-
toms in the previous week. The latter included standard-
ised assessment instruments such as Medical Outcomes 
Survey Short Form—SF-36v2™ [24], for the assessment 
of functional capacity; the pain analog scale [25], for 
the assessment of pain severity; and the fatigue severity 
scale [26], in addition to others not relevant to this paper. 
Participants were asked to fill in the questions about 
symptoms and assessment tools within 48  h of blood 
collection.
Anthropometry
The following physical measures were taken at each 
visit: (i) blood pressure measurements, (Omron HEM-
7015IT)—taken at rest in supine and in standing posi-
tions, both repeated once; (ii) hand grip strength test 
(Jamar J00105 hydraulic hand dynamometer)—three 
repeated 3  s measurements for both hands; (iii) waist 
and hip circumferences measurements (Wessex non-
stretchable sprung tape measure); (iv) standing height 
(Seca 202 height measure); (v) weight and bioimpedance 
(Tanita BC-418 MA body composition analyser, includ-
ing body mass index (BMI)); (vi) spirometry (Vitalograph 
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Pneumotrac 6800 spirometer); (vii) pulse oxymetry 
(FPX050B finger pulse oximeter);
Blood samples collection and analysis
We collected approximately 90–100 ml of blood samples 
from consenting participants, either at the NHS collab-
orating services or through home visits (for the severe 
cases). About 15  ml of blood was used for laboratory 
tests to exclude differential diagnosis, and approximately 
75  ml was processed and stored at the University Col-
lege London-Royal Free Hospital Biobank (UCL-RFH, 
https ://www.ucl.ac.uk/human -tissu e/hta-bioba nks/UCL-
HTA-licen sed-Bioba nks) for the planned studies, and 
for future ethically approved studies. Standard operating 
procedures (SOPs) were followed, and all the stored ali-
quots were anonymised. All laboratory blood tests were 
performed at NHS University Hospitals. GDF15 meas-
urements on participant serum was undertaken at the 
Cambridge Biochemical Assay Laboratory, University of 
Cambridge using antibodies & standards from R&D Sys-
tems (R&D Systems Europe, Abingdon UK). GDF15 was 
measured using a microtitre plate-based two-site electro-
chemiluminescence immunoassay using the MesoScale 
Discovery assay platform (MSD, Rockville, Maryland, 
USA). Based on in house data, the assay detection range 
was 3.0–32,000  pg/ml and between batch imprecision 
ranging from 6.1 to 9.8%. Serum dilutions demonstrate 
linearity.
Statistical analysis
We examined the distribution of GDF15 levels among 
the study groups, at the two time-points, (means and 95% 
confidence intervals (95% CI) or media and interquar-
tile range (IQR)). For comparisons between the distinct 
groups we used t-tests, and for within group compari-
sons at different time points, we used paired t-test. We 
used multiple linear regression analyses for inter-group 
comparisons of GDF15 serum concentration, controlling 
for potential confounding variables; for the correlations 
between GDF15 and indicators of severity, including 
fatigue and pain scores and physical and mental compo-
nent summaries of the SF-36 instrument, we used simple 
linear regression. All analyses were done in Stata Version 
15.
Results
Circulating levels of GDF15 remain stable over time
In considering GDF15 as a potential disease biomarker 
we wished to examine its stability over time (Fig. 1). We 
analysed circulating GDF15 at baseline assessment and 
Fig. 1 GDF15 levels remain stable at longitudinal follow-up. The plots illustrate the circulating GDF15 levels by each participant at baseline (blue) 
and follow-up (orange) assessments after a median of 7.4 months (IQR 6.7–8.8). HC “healthy controls”, ME-mm myalgic encephalomyelitis/chronic 
fatigue syndrome with mild/moderate symptoms, ME-sa myalgic encephalomyelitis/chronic fatigue syndrome severely affected by symptoms, MS 
multiple sclerosis
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follow-up in a sub-sample of 100 randomly selected indi-
viduals, including 40 healthy volunteers, 40 participants 
with ME/CFS and 20 MS cases (Table  1). The median 
time between longitudinal assessments was 7.4  months 
(IQR: 6.7 to 8.8). In the healthy participants, GDF15 lev-
els remained remarkably stable over time with a mean 
value at baseline of 491 pg/ml (95% CI 429–553) and fol-
low-up of 495 pg/ml (95% CI 434–556), p = 0.7. A similar 
pattern was observed in ME/CFS cases, where GDF15 
values were 720  pg/ml (95% CI 625–816) and 670  pg/
ml (95% CI 598–796) at baseline and follow-up respec-
tively (p = 0.5). Among participants with MS which rep-
resents a progressive neurological illness we observed an 
increase in the values from baseline to follow-up of with 
mean circulating GDF15 of 677 pg/ml (95% CI 580–776) 
and 729 pg/ml (95% CI 619–839) (p = 0.01).
GDF15 is increased in patients with severe ME/CFS
Table  2 shows baseline characteristics of the study 
population, this included cases of ME/CFS (n = 150) 
categorised as either mild/moderate disease (n = 100) 
and severely affected (i.e. housebound or bedbound, 
n = 50), MS (n = 50) and “healthy controls” (n = 100). 
The MS cohort were included as a comparative group 
where patients also had a chronic disease associated 
with fatigue. People with MS were on average older 
(49 years old), compared to both ME/CFS and “healthy 
controls” (mean age ~ 42 years old). A larger proportion 
of those with MS smoked (26%), compared to 7.5% of 
ME/CFS and 4% of healthy controls. When comparing 
severe with non-severe cases of ME/CFS, we found a 
lower BMI and higher eGFR in those with more severe 
disease. Other parameters analysed were similar among 
groups. The mean baseline GDF15 values were 491 pg/
ml (95% CI 429–553) in healthy controls, 546  pg/ml 
(95% CI 478–614) in those with MS, 560  pg/ml (95% 
CI 502–617) in those with mild/moderate ME/CFS 
and 602  pg/ml (95% CI 531–674) in severely affected 
ME/CFS patients. There was no significant difference 
between the groups on univariate analysis (Fig.  2). It 
is well established that GDF15 is increased in a num-
ber of physiological and pathological states [17]. Thus, 
we carried out a multivariate analysis to assess if there 
were potential differences in GDF15 levels across the 
groups, after controlling for independent variables, 
such as: sex, age, body mass index, activity levels, 
smoking status, estimated Glomerular Filtration Rate 
(eGFR) and C-reactive protein (CRP)—a frequently 
used circulating marker of inflammation. We found a 
significant direct association between the independent 
variables: age (years), BMI, and CRP, and GDF15 levels; 
and an inverse association between the GDF15 levels 
and eGFR (Table  3). The multivariate analysis results 
show that cases of severe ME/CFS (but not of mild/
moderate cases) have values of GDF15 that are signifi-
cantly higher than the healthy group (P = 0.01). There 
were no significant differences in GDF15 between ME/
CFS cases with mild/moderate disease, MS cases, and 
healthy volunteers (Table 3).
Table 1 Characteristics of participants with follow-up analysis of GDF-15
*P < 0.05, **P < 0.05
All participants (cases and controls)
Variable Mean (95% CI) or number (percentage)
Healthy control (n = 40) Multiple sclerosis (n = 20) ME/CFS (n = 40)
Age (years)** 42.9 (39.1–46.6) 52.7 (49.8–55.6) 44.1 (40.1–48)
BMI (Kg/m2) 25.9 (24.4–27.4) 24.7 (23–26.4) 25.6 (23.8–27.4)
eGFR (ml/min/1.73 m2) 82.7(79.3–86.1) 75.2 (71–79.5) 79.5 (75.5–83.5)
Female sex 23 (57.5%) 15 (75%) 27 (67.5%)
Current smoking 1 (2.5%) 4 (20%) 4 (10%)
ME/CFS cases
Variable Mean (95% CI) or number (percentage)
Non-severe cases (n = 24) Severe cases (n = 16)
Age (years) 47 (42–51.9) 39.8 (33–46.5)
BMI (Kg/m2)* 27.1 (24.9–29.3) 22.9 (20.1–25.7)
eGFR (ml/min/1.73 m2)** 74.7 (69.4–80) 86.5 (81.8–91.2)
Female sex 16 (66.7%) 11 (68.8%)
Current smoking 3 (12.5%) 1 (6.2%)
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Circulating GDF15 is associated with self-reported fatigue
To further delineate the relationship between GDF15 
and symptom severity we examined the correlation 
between circulating GDF15 levels and a variety of self-
reported severity outcomes in our cases and control 
cohort (Table  2). These included the fatigue sever-
ity scale (FSS), pain analog scale and the normalised 
physical and mental summary scores from SF-36v2™ 
instrument. The FSS scores vary from 9 (no fatigue) to 
63 (very severe fatigue). The pain analog scale allows 
scores varying from 0 to 100, with “0” representing 
absence of the symptoms and “100” corresponding to 
extreme pain. For the SF-36v2™ summary scores, the 
lower the normalised scores, the worse is quality of 
life in relation to physical and mental domains. Table 4 
shows the distribution of severity scores of fatigue, 
pain, and SF-36v2™ physical and mental component 
summaries for all groups. Figure 3 illustrates the direct 
correlation between both fatigue and pain intensity 
and GDF15 concentrations in all of the cases of ME/
CFS, MS, and control subjects. An inverse relationship 
between physical wellbeing and GDF15 was present, 
where a lower score on the SF-36v2 ™ indicates reduced 
physical health. In this cohort we did not see a signifi-
cant association between GDF15 and the SF-36v2 ™ 
mental health summary score. The regression lines and 
95% Confidence Intervals show in the charts indicates 
the impact of changes in the levels of GDF15 in the 
symptoms’ severity scores or vice versa. In the subset of 
ME/CFS participants studies we observed a direct cor-
relation between fatigue and GDF15 levels (Fig. 4).  
Table 2 Participant characteristics
*P < 0.01; **P < 0.001
All groups
Variable Mean (95% CI) or number (percentage)
Healthy control (n = 150) Multiple sclerosis (n = 50) ME/CFS (n = 150)
Age (years)** 42 (39.7–44.3) 49.4 (43.3–51.4) 41.6 (39.8–43.5)
BMI (Kg/m2) 25.9 (24.9–26.8) 25.5 (24.3–26.8) 25.4 (24.6–26.3)
eGFR (ml/min/1.73 m2) 82.6 (80.7–84.6) 80.6 (77.9–83.3) 82.5 (80.9–84.2)
C-reactive protein(mg/l) 3.5(2.1–5.0) 2.4(1.8–2.9) 2.8(2.2–3.4)
Female sex 65 (65%) 38 (76%) 112 (74.6%)
Current smoking** 4 (4%) 13 (26%) 11 (7.5%)
ME/CFS cases
Variable Mean (95% CI) or number (percentage)
Non-severe cases (n = 100) Severe cases (n = 50)
Age (years) 41.2 (38.9–43.4) 42.6 (39.4–45.7)
BMI (Kg/m2)* 26.2 (25.2–27.3) 23.7 (22.4–25.0)
eGFR (ml/min/1.73 m2)* 80.5 (78.3–86.2) 86.7 (84.7–88.6)
C-reactive protein(mg/l) 3.1(2.4–3.8) 2.2(1.4–3.1)
Female sex 74 (74%) 38 (76%)
Current smoking 10 (10.3%) 1 (2%)
Fig. 2 GDF15 levels across case and control populations. The 
plot illustrates the range of circulating GDF15 levels measured at 
baseline visits across the four study cohorts. No statistically significant 
difference in GDF15 was observed between the groups. Mean values 
are marked in each group. MS multiple sclerosis, ME/CFSmm myalgic 
encephalomyelitis/chronic fatigue syndrome with mild/moderate 
symptoms, ME/CFSsa myalgic encephalomyelitis/chronic fatigue 
syndrome severely affected by symptoms
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Discussion
GDF15 was initially isolated as a transcript produced 
by activated macrophages, which encoded a protein 
with some homology to the transforming growth fac-
tor beta (TGFβ) superfamily [27]. Increased circulat-
ing GDF15 levels have been observed following physical 
activity and during pregnancy with increases as much as 
40-fold in the latter [18, 28]. Elevations in GDF15 are not 
limited to these physiological states and in the 20  years 
since its discovery, increases in the peptide have been 
reported in a variety of pathological conditions including 
aging, cardiac failure, chronic kidney disease, mitochon-
drial disease and malignancy [16, 17]. However, it was 
the identification of GFRAL, a transmembrane recep-
tor localised to the hindbrain, as the putative target for 
GDF15 and mediator of its weight lowering effects in 
rodents that framed GDF15 as a potential anti-obesity 
therapy [13–15].
As the study of the weight lowering effects of GDF15 
continues it has been intriguing to see that GDF15 is 
not regulated by the nutritional stimuli known to influ-
ence other hormones implicit in energy homeostasis, 
this suggests that GDF15 has not evolved for this bio-
logical purpose [16, 29]. The spectrum of conditions 
reported to be associated with elevations in GDF15 
share a common thread of cellular stress, raising the pos-
sibility that GDF15 may have evolved as part of a stress 
response signal that may incidentally influence energy 
balance. Insights into the role of GDF15 as a signal of cel-
lular stress has been aided by the study of disorders of 
mitochondrial function. Recent work from Chung et  al. 
illustrate that in mice with a muscle specific knockout for 
crif1, a protein integral to the mitoribosomal subunit 39S, 
the ensuing mitochondrial unfolded protein response 
mediates increased GDF15 expression in a process that 
is dependent on the activation of the CHOP, a stress 
induced pro-apoptotic transcription factor [30]. Simi-
larly, in vitro, GDF15 expression is responsive to activa-
tion of the integrated stress response (IRS), an adaptive 
response to stressful stimulus in eukaryotic cells [29, 
31]. Markedly increased circulating GDF15 values have 
now been reported in a variety of inherited mitochon-
drial diseases [32–35]. The apparent symptom overlap 
between patients affected by ME/CFS and mitochondrial 
disorders has generated discussion into the possibility of 
a shared pathophysiology between the respective con-
ditions [36]. Considering GDF15’s potential as a novel 
marker of mitochondrial dysfunction, we hypothesised 
that it may represent a biomarker of mitochondrial stress 
in ME/CFS [37].
Table 3 Multivariate linear regression on the effects of being a case on GDF15 concentrations
p-value < 0.05 was considered statistically significant and represented in italics
a Difference between GDF15 concentration in exposure group and baseline variable. Baseline concentration in GDF15 in “healthy controls” with baseline levels of 
exposure = 511.5 pg/ml
b Log-likelihood test
c By unit of change, e.g. year of age
Variable Coefficienta (pg/ml) 95% confidence interval p-valueb
Case status 0.08
 Healthy control –
 MS 34.3 − 33.7 to 102.4 0.3
 ME/CFS mild/moderate 48.3 − 9.0 to 105.6 0.1
 ME/CFS severe 91.2 19.6 to 162.7 0.01
Sex (female) − 28.5 − 73.7 to 16.8 0.2
Agec (years) 3.9 1.8 to 6.1 < 0.0001
Body mass index (Kg/m2)c 3.3 − 1.4 to 8.0 0.2
Activity level 0.05
 Little activity –
 Average activity 66.7 7.2 to 126.3 0.03
 Active 45.2 − 8.7 to 99.1 0.1
Smoking status 0.04
 Never smoked –
 Previous smoker 7.7 − 38.0 to 53.3 0.7
 Current smoker 92.6 19.2 to 165.9 0.01
CRP (mg/L) 6.9 2.5 to 11.2 0.002
eGFR(ml/min/1.73 m2) − 4.0 − 6.3 to − 1.6 0.001
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In our analysis, we included both healthy control sub-
jects in addition to a cohort of patients diagnosed with 
multiple sclerosis. The observation that GDF15 meas-
urements do not significantly change over longitudinal 
follow-up of patients affected with ME/CFS reassures 
us of its value as a potential biomarker. Interestingly in 
the subset of participants with MS we saw that GDF15 
increased significantly from baseline assessment. GDF15 
levels are significantly increased in a cohort of ME/CFS 
patients categorised as having severe disease when com-
pared to a healthy control group. The observation that 
GDF15 levels associate with severe rather than mild/
moderate disease is indicative of a relationship between 
ME/CFS disease severity and GDF15. These findings 
mirror reports from the study of primary mitochondrial 
disorders with Yatsuga et  al. [34] demonstrating a posi-
tive correlation between GDF15 and both the Japanese 
Mitochondrial Disease Rating Scale and the Newcastle 
Mitochondrial Scale for Adults, which represent semi-
quantitative clinical rating scales. In the case of our ME/
CFS study cohort the fatigue severity scale correlated 
with GDF15 levels, these findings lend further support 
for a role for GDF15 as a marker of symptom severity in 
ME/CFS.
However, it is important to note that in contrast to 
the levels observed in primary disorders of mitochon-
drial function, the mean GDF15 levels measured in our 
ME/CFS cohort are many fold lower [33, 35]. This is not 
surprising given the widespread mitochondrial dysfunc-
tion observed in disorders such as Leigh’s syndrome, 
but it suggests that significant impairment of mitochon-
drial function may not be as prominent a feature of ME/
CFS. Certainly, enrichment for pathogenic mutations in 
mitochondrial DNA has not been seen among patients 
affected by ME/CFS [38]. However, there are a num-
ber of conflicting reports on the relationship between 
Fig. 3 Linear regression charts between levels of GDF15 and severity of symptoms reported by study participants at baseline time-point. The 
charts illustrate the regression lines between levels of circulating GDF15 (y-axis) and reported symptoms (x-axis) in all participants (healthy control, 
Multiple Sclerosis and ME/CFS (mild and severe disease). Symptoms measured by distinct validated instruments, at the time of blood collection 
(baseline time-point) and 95% Confidence Intervals. The statistical significance of the tested correlations between levels of GDF15 and measured 
symptoms are also presented in the charts (P values)
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mitochondrial dysfunction and disease severity in ME/
CFS [12]. We expect that the emergence of GDF15 as a 
biomarker of mitochondrial dysfunction will support 
ongoing efforts to study this relationship.
In ME/CFS it is not clear what tissue or tissues may 
be contributing to the elevated levels GDF15 observed 
in severe disease. We know that in humans, GDF15 is 
expressed in a wide range of tissues with highest expres-
sion in the liver, kidney, prostate, colon, adipose tissue 
and placenta [39]. Interestingly, GDF15 or MIC-1 was 
initially cloned from a macrophage cell line. However, 
Sweetman et al. [40] did not report a significant change in 
GDF15 transcription in PBMCs from ME/CFS patients. 
We have seen in primary mitochondrial disorders asso-
ciated with overt myopathy that GDF15 expression is 
massively upregulated in skeletal muscle and this is asso-
ciated with an increase in circulating levels [32]. How-
ever, there are no reports of GDF15 expression in muscle 
or other tissues of humans with ME/CFS. Further study is 
required to determine the source of increased circulating 
GDF15 observed in a subset of ME/CFS patients.
Thus far we have considered GDF15 as a potential 
biomarker in ME/CFS rather than a contributing fac-
tor to the symptomatology observed in this cohort. 
Fatigue is frequently reported in the conditions associ-
ated with increased GDF15, although the relationship 
between fatigue in these disease states and GDF15 has 
not been formally studied in humans. Reduced locomo-
tor activity has been reported in transgenic mice that 
over-express GDF15 and wild-type animals exposed 
to pharmacological doses of the peptide [19, 20]. The 
reason for the decreased activity has not been eluci-
dated, however, it is speculated that this may be reflec-
tive of reduced food seeking behaviour. In humans, 
understanding whether GDF15 contributes to the 
symptoms of fatigue or is simply a circulating marker 
of the underlying disease process will necessitate fur-
ther study. However, in time, both the administration of 
Fig. 4 Linear regression charts between levels of GDF15 and severity of symptoms reported by study participants with ME/CFS at baseline 
time-point. The charts illustrate the regression lines between levels of circulating GDF15 (y-axis) and reported symptoms (x-axis) among the ME/CFS 
patient cohort only, including participants in the mild and severe disease categories. Symptoms were measured by distinct validated instruments, 
at the time of blood collection (baseline time-point) and 95% Confidence Intervals. The statistical significance of the tested correlations between 
levels of GDF15 and measured symptoms are also presented in the charts (P values)
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GDF15 to humans and/or the pharmacological manip-
ulation of the GDF15-GFRAL axis in specific diseases 
that increase GDF15 could provide valuable insight 
on the contribution of GDF15 to symptoms of fatigue. 
Certainly, in ME/CFS the biological relevance of the 
circulating levels at which GDF15 we have observed is 
unclear.
Conclusions
We have demonstrated that under resting conditions cir-
culating GDF15 is increased among patients with severe 
ME/CFS and levels of GDF15 remain stable over a period 
of months. Further study is required to establish the tis-
sue/tissues contributing to the elevations in GDF15, and 
the mechanism by which it is increased in ME/CFS. It 
will also be important to investigate whether an elevation 
in GDF15 levels could contribute to any of the symptom-
atology of ME/CFS, even if only in a subset of patients.
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